Home How cost pressures under Obamacare can be a boon to the biotech industry
 

Keywords :   


How cost pressures under Obamacare can be a boon to the biotech industry

2014-09-16 22:22:54| Biotech - Topix.net

President Barack Obama's signature Affordable Care Act has spurred plenty of attacks on the pharmaceutical industry, but it has also created opportunities, according to Flagship Ventures partner Harry Wilcox. The recent launches of drugs with high up-front costs have revived the longstanding debate over how much new medicines ought to cost.

Tags: to the cost industry

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
07.05Net Sales Decrease for IFF in Q1 2024
07.05Coty: Q3 2024 Financials
07.05Reeves: Government 'gaslighting' people on economy
06.05Asahi Photoproducts wins FTA Sustainability Excellence Award
06.05Sally Hansen Links with Ring Pop for Limited Edition Collection
06.05Bertz selected as new Executive Director
06.05Sun Bum Teams with Skin Cancer Foundation to Provide Free Skin Exams for Skin Cancer Awareness Month
06.05Boeing faces new probe over 787 inspection doubts
More »